<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03574545</url>
  </required_header>
  <id_info>
    <org_study_id>CVAY736A2101</org_study_id>
    <nct_id>NCT03574545</nct_id>
  </id_info>
  <brief_title>Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis</brief_title>
  <official_title>A Randomized, Open Label, Multiple Dose, Parallel Group Study to Assess the Safety and Pharmacokinetic Comparability of Two VAY736 Drug Products in Patients With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and pharmacokinetic comparability of two VAY736 drug
      products in patients with rheumatoid arthritis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2018</start_date>
  <completion_date type="Anticipated">February 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 10, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as measured by the number of patients with adverse events</measure>
    <time_frame>Week 0 - 112</time_frame>
    <description>The number of patients with adverse events after repeated subcutaneous (s.c) injections of a fixed dose of ianalumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic comparability at steady state - AUCtau</measure>
    <time_frame>Week 8 - 12</time_frame>
    <description>The area under the serum ianalumab concentration-time curve from time zero to the end of the dosing interval (AUCtau)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic comparability at steady state - Cmax</measure>
    <time_frame>Week 8 - 12</time_frame>
    <description>Observed maximum serum concentration of ianalumab following drug administration (Cmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic comparability after the first dose - AUCtau</measure>
    <time_frame>Week 0 - 4</time_frame>
    <description>The area under the serum ianalumab concentration-time curve from time zero to the end of the dosing interval (AUCtau)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic comparability after the first dose - Cmax</measure>
    <time_frame>Week 0 - 4</time_frame>
    <description>Observed maximum serum concentration of ianalumab following drug administration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic comparability after the first dose - Tmax</measure>
    <time_frame>Week 0 - 4</time_frame>
    <description>Time to reach the maximum concentration after drug administration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic comparability of two ianalumab drug products after the last dose - AUCinf</measure>
    <time_frame>Week 8 - 12</time_frame>
    <description>The area under the serum ianalumab concentration-time curve from time zero to infinity (AUCinf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic comparability after the last dose - Tmax</measure>
    <time_frame>Week 8 - 12</time_frame>
    <description>Time to reach the maximum concentration after drug administration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic comparability after the last dose - T1/2</measure>
    <time_frame>Week 8 - 12</time_frame>
    <description>The terminal elimination half-life (T1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic comparability at the end of each dosing interval - Ctrough</measure>
    <time_frame>Week 0 - 12</time_frame>
    <description>Observed minimum serum ianalumab concentration following drug administration (Ctrough)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic effect as measured by B-cell level</measure>
    <time_frame>Week 0 - 112</time_frame>
    <description>Circulating B cells (CD19+)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity as measured by Anti-Drug Antibodies</measure>
    <time_frame>Week 0 - 112</time_frame>
    <description>Anti-ianalumab antibodies (ADA); incidence of ADA positive patients and correlation with AEs, PK and clinical outcomes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Reference VAY736 Drug Product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Powder for solution for injection / infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test VAY736 Drug Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solution for injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ianalumab</intervention_name>
    <description>Human monoclonal antibody (mAb) of type IgG1/κ binding to B-cell activating-receptor (BAFF-R)</description>
    <arm_group_label>Reference VAY736 Drug Product</arm_group_label>
    <arm_group_label>Test VAY736 Drug Product</arm_group_label>
    <other_name>VAY736</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fulfill 2010 ACR/EULAR criteria for RA Aletaha et al 2010 at Screening

          -  Active disease defined as ≥ 2 swollen joints (of 58 evaluable joints) and ≥ 2 tender
             joints (of 60 evaluable joints) despite stable MTX ≤ 25 mg/week and/or
             hydroxychloroquine ≤ 400 mg/day treatment for at least 2 months prior to randomization

        Exclusion Criteria:

          -  Prior or previous use of (specific dosages and intervals prior to study start may
             apply): other investigational drugs, B-cell depleting therapy (e.g. rituximab),
             monoclonal antibodies (mAb), i.v. / s.c. Ig, thymoglobulin, i.v. or oral
             cyclophosphamide, oral cyclosporine, soluble cytokine receptors, azathioprine.

          -  Currently receiving prednisone &gt;10 mg/day (or equivalent oral glucocorticoid) or dose
             adjustment within 2 weeks prior to randomization

          -  Active viral, bacterial or other infections requiring systemic treatment at the time
             of screening or enrollment, or history of recurrent clinically significant infection
             or of bacterial infections with encapsulated organisms

          -  Receipt of live/attenuated vaccine within a 2-month period before randomization

          -  Pregnant or nursing (lactating) women

          -  Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant, unless they are using highly effective methods of contraception
             from screening and for 4 months after stopping of investigational drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amman</city>
        <zip>11941</zip>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Jordan</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 21, 2018</study_first_submitted>
  <study_first_submitted_qc>June 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2018</study_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>VAY736</keyword>
  <keyword>Ianalumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

